Biotech | May 02, 2022
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical
Avacc 3 has significant advantages over existing whooping cough vaccines
Avacc 3 has significant advantages over existing whooping cough vaccines
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
Subscribe To Our Newsletter & Stay Updated
